Patent Protection Strategies
Maximising Product Revenues

By Peter Norman

Table of Contents
Peter Norman MBA, PhD

Peter Norman is a pharmaceutical consultant and analyst based in Burnham Beeches, near Windsor, England, with specialist knowledge of the respiratory disease and inflammation markets. He has written and presented widely on various aspects of respiratory disease and on the analysis of therapeutic markets.

Dr. Norman has over 25 years’ experience of the pharmaceutical industry in both R&D and competitive intelligence. His publications include many reviews and management reports, sixteen original scientific papers and eleven patents. Dr. Norman holds science degrees from Cambridge University and Brunel University plus an M.B.A. degree from the Open University.
# Table of Contents

## PATENT PROTECTION STRATEGIES

### Executive Summary 10

- The need for patent protection 10
- Current patent protection mechanisms 10
- Offensive strategies 12
- Case Histories 13
- Optimizing Revenue Returns 14
- Future outlook 15

### Chapter 1  The need for patent protection 18

- Summary 18
  - Introduction 19
    - The costs of drug development 19
    - The drug lifecycle 21
    - The need to optimize returns from successful drugs 22
    - The dependence on blockbuster revenues 23
    - The impact of generics 25
    - Aggressive generic companies 30

### Chapter 2  Current patent protection mechanisms 34

- Summary 34
  - Introduction 35
  - Patent basics 35
    - Requirements for a therapeutic patent 36
    - Four types of pharmaceutical patent 37
  - Legal patent frameworks 38
    - United States 38
    - Europe/PCT 40
Japan 41
Other markets 41

**Patent term extensions** 42
US patent term extensions 43
Supplementary Protection Certificates 44
Japanese Patent term extensions 46
Pediatric exclusivity 46

**Orphan Drug legislation** 48

**Regulations for market entry of generics** 51
United States 52
  - Hatch Waxman 52
  - ANDAs 52
  - Paragraph IV challenges 54
Europe 55
Japan 55

**Biological Products and Biosimilars** 57
United States 59
Europe 61

**Freedom to operate** 62

---

**Chapter 3  Offensive strategies**

Summary 66

Introduction 67

**Filing strategies** 68
Early or late filing? 68
Overlapping claims 69
Broad claims or narrow claims? 71

**Exploitation of term extension legislation** 73

**Product patents** 75
Subsidiary patents 76
Crystalline form patents 78
Salt and solvate patents 80
Enantiomer patents 82
Prodrug and antedrug patents 82

**Process patents** 84

**Formulation patents** 85
Improved formulations 85
Drug Combinations 87
  - "Obvious" antihypertensive combinations 87
  - Advair 88
  - Antidiabetic agents 89
New delivery routes 89

**Method of Use patents** 90
List of Tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1.1</td>
<td>Drugs generating 2006 revenues in excess of $3 billion</td>
<td>25</td>
</tr>
<tr>
<td>Table 2.2</td>
<td>Possible term extensions in major markets</td>
<td>43</td>
</tr>
<tr>
<td>Table 2.3</td>
<td>Selected high revenue generating Orphan drugs</td>
<td>50</td>
</tr>
<tr>
<td>Table 2.4</td>
<td>Orphan drug legislation in the major markets</td>
<td>51</td>
</tr>
<tr>
<td>Table 5.5</td>
<td>Amgen's key Epogen patents</td>
<td>119</td>
</tr>
</tbody>
</table>